Pfizer Licenses Shelved Seagen CD228 ADC to Medicus

Pfizer (NYSE: PFE) is handing its shelved Seagen antibody-drug conjugate PF-08046031, also called CD228V, to Medicus Pharma (Nasdaq: MDCX) in a co-development deal that could top $1 billion. Medicus pays $12 million upfront and another $15 million on the deal’s first anniversary, while Pfizer chips in $2 million of development funding. Pfizer keeps patent ownership, budget oversight, and a cut of any future sublicensing proceeds; Medicus takes on the manufacturing, regulatory, and commercialization work.

The headline number matters less than the near-term cash, as this guide to licensing-deal economics explains. Only $12 million of the “up to $1 billion” is guaranteed at closing; the rest is development, regulatory, and sales milestones Pfizer collects only if the drug reaches market, plus low-double-digit tiered royalties. For Medicus, a microcap with about 63 million shares outstanding that closed down 34% at $0.17 on roughly 97 million shares traded, the real cost is the $27 million it owes Pfizer over the next year. That exceeds the company’s market value, which sat near $11 million after Thursday’s slide.

CD228V is a vedotin-class antibody drug conjugate: a humanized antibody (hL49) that binds CD228, also called melanotransferrin, with an average of four molecules of the cell-killing payload MMAE attached. CD228 is highly expressed on melanoma cells and several other solid tumors, and no approved drug yet targets it. The vedotin linker-and-payload design is the same one behind Seagen’s approved Adcetris and Padcev, so the pharmacology is well understood even if this particular target is unproven. The asset arrived with Pfizer’s $43 billion Seagen acquisition, and Pfizer scrapped the Phase 1 trial, launched in May 2025 in advanced melanoma with expansion into lung, head-and-neck, and esophageal cancers, earlier this year.

The target is real but unproven. Pfizer is not abandoning CD228 entirely. It still runs PF-08046049, a CD228 x 4-1BB bispecific in Phase 1 for melanoma. But the move is clearly part of a Seagen portfolio prune, after a separate Seagen-inherited ADC failed a Phase 3 lung cancer readout. Medicus CEO Raza Bokhari called the deal “a defining milestone” that moves the company into precision oncology.

The risk is plain: Medicus must now fund a clinical-stage ADC on a balance sheet worth less than its first-year obligation, and Thursday’s 34% drop suggests the market is already pricing in dilution. Watch whether Medicus raises capital to cover the $27 million, and whether it restarts the Phase 1 that Pfizer walked away from.

Source: Fierce Biotech

What It Means for the Trade

Read this as two stories stapled together, because the markets involved are different sizes. The Pfizer side is a portfolio-pruning footnote: offloading a shelved Phase 1 asset for $12 million upfront plus upside-only milestones is standard post-acquisition housekeeping for a company that paid $43 billion for Seagen and is now rationalizing which ADCs deserve its manufacturing and clinical dollars. CD228V joins the list of Seagen-inherited programs that didn’t survive Pfizer’s triage — remember that a separate Seagen ADC failed a Phase 3 lung readout earlier in 2026 — and the retained CD228 x 4-1BB bispecific tells you Pfizer sees signal in the target but not in this construct’s risk-reward.

The Medicus side is where the trade lives, and it’s a strange one. A microcap with an ~$11 million post-selloff market value committed to $27 million in near-term payments plus the full cost of restarting and running a Phase 1 ADC program — the market’s 34% vote (on 97 million shares, more than the entire float traded) is a blunt dilution warning, and realistically the financing comes at prices well below even $0.17. The structure — Medicus does the work, Pfizer keeps the patents and takes royalties plus a sublicensing cut — means MDCX shareholders are buying an option on a rejected asset where the majority of any terminal value flows elsewhere. There are versions of this that work (small biotechs have revived shelved assets when the original owner’s reason for stopping was portfolio fit rather than data), but the base rate is unkind, and the financing path must clear before the science even gets tested.

For anyone screening: this is a sub-$15 million market cap with an upcoming raise. The only reason to be involved pre-financing is a conviction that Pfizer killed the program for capacity reasons and the Phase 1 melanoma data (never fully disclosed publicly) was better than the “scrapped” label implies. That’s a lottery ticket with extra steps.

Asset Context: What CD228V Actually Is

The pharmacology is the most credible thing here. Vedotin-class ADCs (MMAE payload, cleavable linker, ~4 drug-antibody ratio) are the most-validated ADC chemistry in existence — Adcetris in lymphoma and Padcev in bladder cancer both run on it, and Seagen’s manufacturing and regulatory experience with the platform transfers directly. The novel variable is the target: CD228/melanotransferrin, highly expressed on melanoma and a set of other solid tumors, with no approved drug against it. Target novelty is both the upside (first-mover in an unclaimed antigen, potential best-in-class positioning if expression correlates with response) and the risk (unvalidated antigens fail at high rates in Phase 1 because target biology in humans diverges from preclinical models, and MMAE’s known toxicities — neutropenia, neuropathy — constrain how aggressively you can dose to compensate for imperfect target biology).

The bispecific sibling is the tell. Pfizer keeping PF-08046049 (CD228 x 4-1BB) alive in the clinic while offloading the plain ADC suggests the company’s view: the antigen is real, but the vedotin construct’s therapeutic index didn’t clear Pfizer’s bar for its capital. Whether Medicus can prove that judgment wrong on a microcap budget is the entire question.

Risks and What Could Go Wrong

Essentially everything: (1) The financing itself — $27 million owed within a year against an $11 million market cap means a raise at dilutive prices or convertible structure; the financing terms will tell you how desperate the position is. (2) Restart costs — a new Phase 1 with manufacturing transfer from Pfizer’s network typically runs well beyond the deal’s $2 million development funding before the first patient is dosed. (3) The data Pfizer walked from — we don’t know why the original trial stopped beyond “portfolio”; if the reason was a safety finding or anemic early signals, Medicus inherits it. (4) Milestone-weighted “value” — the $1 billion headline is marketing; treat the deal as $12-27 million of real money against a high-failure-rate asset. (5) Comparable-asset signal — CD228-targeted programs have no approved precedent anywhere; there is no read-through hedge if it fails.

For Pfizer holders, the story is mildly positive — disciplined capital allocation, however small — but immaterial at PFE’s scale. This one is a curiosity trade, not a thesis.